Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HUTCHMED (China) (HCM) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for HUTCHMED (China) (HCM) over the last 12 years, with Q2 2025 value amounting to $154.0 million.

  • HUTCHMED (China)'s Cash & Equivalents fell 2451.3% to $154.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $154.0 million, marking a year-over-year decrease of 2451.3%. This contributed to the annual value of $283.6 million for FY2024, which is 947.69% down from last year.
  • HUTCHMED (China)'s Cash & Equivalents amounted to $154.0 million in Q2 2025, which was down 2451.3% from $107.5 billion recorded in Q4 2024.
  • Over the past 5 years, HUTCHMED (China)'s Cash & Equivalents peaked at $107.5 billion during Q4 2024, and registered a low of $113433.7 during Q4 2023.
  • For the 5-year period, HUTCHMED (China)'s Cash & Equivalents averaged around $10.9 billion, with its median value being $235.6 million (2021).
  • In the last 5 years, HUTCHMED (China)'s Cash & Equivalents crashed by 9985.94% in 2023 and then surged by 9481262523.36% in 2024.
  • Quarter analysis of 5 years shows HUTCHMED (China)'s Cash & Equivalents stood at $235.6 million in 2021, then crashed by 65.77% to $80.7 million in 2022, then crashed by 99.86% to $113433.7 in 2023, then soared by 94812625.23% to $107.5 billion in 2024, then crashed by 99.86% to $154.0 million in 2025.
  • Its Cash & Equivalents was $154.0 million in Q2 2025, compared to $107.5 billion in Q4 2024 and $204.0 million in Q2 2024.